13therapeutics Is Selected to Present at 2011 BIO International Convention.

Share Article

13therapeutics, Inc. has been selected to present at the 2011 BIO International Convention which takes place in Washington DC June 27-30 at the Walter E. Washington Convention Center. The company will be discussing its portfolio of anti-inflammatory therapeutics that have shown efficacy in treating a variety of inflammatory and auto-immune diseases, including Rheumatoid Arthritis, Lupus, Uveitis, and Sepsis. 13therapeutics is moving its lead compound, designated P13, forward for the treatment of hearing related disorders, including Otitis Media, Noise Induced Hearing Loss, and Age Related Hearing Loss.

13therapeutics, Inc. has been selected to present at the 2011 BIO International Convention which takes place in Washington DC June 27-30 at the Walter E. Washington Convention Center. The company will be discussing its portfolio of anti-inflammatory therapeutics that have shown efficacy in treating a variety of inflammatory and auto-immune diseases, including Rheumatoid Arthritis, Lupus, Uveitis, and Sepsis. 13therapeutics is moving its lead compound, designated P13, forward for the treatment of hearing related disorders, including Otitis Media, Noise Induced Hearing Loss, and Age Related Hearing Loss.

The company will also be exhibiting in the Oregon Booth, along with other Oregon Biotech organizations, and it will be meeting with current and potential financial, pharmaceutical, manufacturing and contract research partners.
“We are very pleased to have been chosen to present at the 2011 BIO International Convention”, said Tom Bruggere Chairman and CEO. “The convention allows us to showcase our unique and important science to thousands of key participants in the biotech industry”.

13therapeutics has an innovative platform for discovering and enhancing peptides, derived from naturally occurring pathogens (e.g., bacteria, viruses, fungi), which modulate the human immune response. This platform has produced a portfolio of peptides with demonstrated immune-regulatory activity and with varying mechanisms of action. These peptides have potential application for treatment of both acute and chronic inflammatory diseases. Many of the company’s peptides are capable of multiple methods of delivery, have shown serum stability, and have other desired features of clinical therapeutics.

About the Bio International Convention

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry.

The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities. Past speakers include President George W. Bush, President Bill Clinton, Michael J. Fox, Sir Elton John, Her Majesty Queen Noor of Jordan, and General Colin Powell, among many others. The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world's largest biotechnology exhibition - the BIO Exhibition.
About 13therapeutics

13therapeutics is a research and drug development company identifying and characterizing novel anti-inflammatory peptide therapeutics for unmet medical needs with high commercial potential. Founded in 2008, the Portland, Oregon-based company is a spin-out from the Oregon Health and Science University (OHSU). The management team and research scientists of 13therapeutics are veterans of bioscience, research and technology.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tom Bruggere

Steve Karakas
NONBOX
Email >
Visit website